

Supplementary Materials for

Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPR-mediated direct in vivo screening

Guangchuan Wang, Ryan D. Chow, Lupeng Ye, Christopher D. Guzman, Xiaoyun Dai, Matthew B. Dong, Feng Zhang, Phillip A. Sharp, Randall J. Platt, Sidi Chen

Published 28 February 2018, *Sci. Adv.* **4**, eaao5508 (2018)
DOI: 10.1126/sciadv.aao5508

The PDF file includes:


- fig. S1. Representative full-spectrum MRI series of livers from PBS-, vector-, and mTSG-treated mice.
- fig. S2. Additional bright-field images of mTSG-treated livers with GFP overlay.
- fig. S3. Representative full-slide scanning images of mouse liver sections in PBS, vector, and mTSG treatment groups.
- fig. S4. Representative histology and immunohistochemistry images of mouse liver sections in PBS, vector, and mTSG groups.
- fig. S5. MIP capture sequencing statistics and indel size distribution of mTSG livers.
- fig. S6. Mutated sgRNA sites across all liver samples from mice treated with AAV-mTSG library.
- fig. S7. Heat map of gene-level sum variant frequency across all mTSG liver samples.
- fig. S8. Additional co-mutation analysis.
- fig. S9. Heat map of all unique variants across all mTSG liver samples.
- fig. S10. Investigation and comparison of single or combinatorial knockout of screened TSGs in liver tumorigenesis.
- fig. S11. Mutant clonality and clustering analysis.
- Legends for tables S1 to S17

Other Supplementary Material for this manuscript includes the following:
(available at advances.sciencemag.org/cgi/content/full/4/2/eaao5508/DC1)

- table S1 (Microsoft Excel format). DNA sequences of sgRNA spacers in mTSG library.
- table S2 (Microsoft Excel format). Raw read counts of mTSG plasmid library.
- table S3 (Microsoft Excel format). Tumor volume data as measured by MRI.
- table S4 (Microsoft Excel format). Survival data for PBS-, vector-, or mTSG-treated animals.
- table S5 (Microsoft Excel format). Tumor area data as measured by tissue histology.
- table S6 (Microsoft Excel format). Sequence information and annotation for all MIPs used in the study.
- table S7 (Microsoft Excel format). Metadata for all of the 133 sequenced samples.
- table S8 (Microsoft Excel format). MIP capture sequencing coverage statistics across all predicted cutting sites of sgRNAs in AAV-mTSG library.
- table S9 (Microsoft Excel format). Raw indel variant calls of all samples with targeted capture sequencing before filtering.
- table S10 (Microsoft Excel format). sgRNA-level sum indel frequency table for all samples with targeted capture sequencing.
- table S11 (Microsoft Excel format). sgRNA-level binary MS calls in livers from mice treated with AAV-mTSG library.
- table S12 (Microsoft Excel format). Gene-level binary MG calls in livers from mice treated with AAV-mTSG library.
- table S13 (Microsoft Excel format). Co-occurrence analysis of MG pairs in livers from mice treated with AAV-mTSG library.
- table S14 (Microsoft Excel format). Correlation analysis of gene-level sum indel frequency in livers from mice treated with AAV-mTSG library.
- table S15 (Microsoft Excel format). Mutant frequencies for all unique variants present across all mTSG liver samples.
- table S16 (Microsoft Excel format). Spearman rank correlation matrix for five individual liver lobes within a single mouse.
- table S17 (Microsoft Excel format). Mutant frequencies for all unique variants present in five individual liver lobes from a single mouse.

Figure S1

A



B




fig. S1. Representative full-spectrum MRI series of livers from PBS, vector and mTSG-treated mice. (A) Full-spectrum MRI slices from representative PBS, vector, and mTSG-treated mice. (B) Dot plot of the sum tumor volume per mouse (in mm³) in mice treated with PBS (black, n = 3), vector (gray, n = 3), or mTSG library (blue, n = 4). mTSG-treated mice had significantly higher tumor burdens than PBS (one-sided Mann-Whitney test, $p = 0.0286$) or vector-treated animals ($p = 0.0286$).

Figure S2

AAV mTSG livers

Brightfield GFP




fig. S2. Additional brightfield images of mTSG-treated livers with GFP overlay. Additional brightfield images with GFP fluorescence overlay (green) of livers from 15 mTSG-treated mice at the time of sacrifice.

Figure S3




fig. S3. Representative full-slide scanning images of mouse liver sections in PBS, vector, and mTSG treatment groups. Full slide scans of liver sections from PBS, vector and mTSG-treated mice. Two representative mice from each group are shown. Some brain sections are also present in the same scanned field, noted with asterisks. PBS samples did not have any detectable nodules, while vector-treated samples occasionally had developed small nodules. In contrast, mTSG-treated samples were replete with tumors. Scale bar is 2 mm.

Figure S4

A




Figure S4 continued

B




Figure S4 continued

C





fig. S4. Representative histology and immunohistochemistry images of mouse liver sections in PBS, vector, and mTSG groups. (A) Representative liver sections from PBS, vector, and mTSG-treated mice with hematoxylin and eosin staining. The vector sample and mTSG replicate 4 pictured here are from the same mice shown in Figure 2D. Scale bar is 1 mm for low magnification images, 200 μm for high magnification images. (B) Representative liver sections from PBS, vector, and mTSG-treated mice with Ki67 staining. Sections correspond to the same mice shown in Fig. S4A. Scale bar is 1 mm for low magnification images, 200 μm for high magnification images. (C) Representative liver sections from PBS, vector, and mTSG-treated mice with pan-cytokeratin AE1/AE3 staining. Sections correspond to the same mice shown in fig. S4A. Scale bar is 1 mm for low magnification images, 200 μm for high magnification images.

Figure S5

A



B




fig. S5. MIP capture sequencing statistics and indel size distribution of mTSG livers. (A) Plot of median \log_2 sequencing coverage across all sequenced samples in amplicons targeted by the 266 MIPs (black dots). MIPs were designed to amplify the genomic regions flanking the predicted cut sites of each sgRNA. 95% confidence intervals for the median are depicted with blue lines. Median read depth across all MIPs approximated a lognormal distribution, indicating relatively even capture of the target loci. (B) Heat map detailing indel size distribution and abundance across all mutated sgRNA sites from mTSG-treated liver samples. Positive indel sizes denote insertions, while negative indel sizes indicate deletions. Depicted values are in terms of total \log_2 normalized reads per million (rpm) for each sample. Most variant reads are deletions (80.8%) compared to insertions (19.2%).

Figure S6




Figure S6 continued




fig. S6. Mutated sgRNA sites across all liver samples from mice treated with AAV-mTSG library. Waterfall plots of mutated sgRNA sites across all 33 mTSG-treated liver samples, sorted by sum variant frequency. Four samples (mTSG liver 17, mTSG liver 54, mTSG liver 96 and mTSG liver 115) are not shown, as these samples were not found to have any mutated sgRNA sites per our stringent variant calling strategy. The extensive mutational heterogeneity amongst the liver samples is suggestive of strong positive selective forces acting on diverse loss-of-function mutations induced by the mTSG library.

Figure S7




fig. S7. Heat map of gene-level sum variant frequency across all mTSG liver samples. Heat map depicting sum variant frequencies for the 56 genes represented in the library, across all mTSG liver samples. Genes are ordered according to average sum variant frequency (top to bottom row).

Figure S8







fig. S8. Additional co-mutation analysis. (A) Upper-left triangle: heat map of the pairwise Pearson correlation of sum % variant frequency for each gene, averaged across sgRNAs. Lower-right triangle: heat map of $-\log_{10}$ p-values by t-distribution to evaluate the statistical significance of the pairwise correlations. (B) Scatterplot of the Pearson correlation for each gene pair, plotted against $-\log_{10}$ p-values. (C) Scatterplot of the cooccurrence rates for each gene pair, excluding all pairs involving *Trp53*, plotted against $-\log_{10}$ p-values by hypergeometric test. (D) Scatterplot of the Spearman correlations for each gene pair, excluding all pairs involving *Trp53*, plotted against $-\log_{10}$ p-values.

fig. S9. Heat map of all unique variants across all mTSG liver samples. Variant frequencies for all unique variants identified across mTSG liver samples, after square-root transformation for visual clarity. Rows denote unique variants, while columns denote different liver samples. Data was clustered using Euclidean distance and average linkage. 70.15% (416/593) of the variants were sample-specific, while 29.85% (177/593) variants were found across multiple samples.

Figure S10




fig. S10. Investigation and comparison of single or combinatorial knockout of screened TSGs in liver tumorigenesis. (A) Schematics of the design and cloning of liver-specific AAV-CRISPR vectors to functionally study target genes for their potential roles as independent and synergistic drivers of liver tumor in immunocompetent mice. The AAV-CRISPR plasmids contain two U6 promoter-driving sgRNA expression cassettes, with the 1st sgRNA targeting *Trp53*, and another one either as a non-targeting sgRNA (NTC + *Trp53*) or a geneX-targeting sgRNA (GeneX + *Trp53*). The plasmids also contained a liver-specific TBG promoter driving a co-cistronic expression cassette of firefly luciferase (FLuc) and Cre recombinase. AAVs were generated with these plasmids and injected intravenously into LSL-Cas9 mice. (B) Representative bioluminescence images of LSL-Cas9 mice injected with AAV9 that contains liver-specific TBG promoter-driving Cre and CRISPR dual-sgRNAs expression cassettes. Undetectable or weak luciferase activity was detected in NTC + *Trp53* AAV treated mice (n = 8) at 121 days post-injection, whereas persistent and robust luciferase activity was detected in the mice that were injected with the top scoring genes (GeneX + *Trp53*) or the highly co-mutated gene pairs from the screen. (C) Quantification of bioluminescence intensities of AAV-CRISPR injected LSL-Cas9 mice at 121 days post-injection are shown in units of photons/sec/cm²/sr (Data represented as mean ± SEM). The mice that were injected with AAVs targeting the top screened genes or the highly correlated gene pairs had robust luciferase activity after 121 days of injection, indicating the role of these TSGs in accelerating development of tumors compared to NTC controls (two-sided unpaired *t* test, N.S. $p > 0.05$, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$). In comparison to NTC (n = 7), *Cic* (n = 4, $p = 0.018$), *Pik3r1* (n = 7, $p = 0.015$), *Pten* (n = 4, $p = 0.011$), *Stk11* (n = 8, $p = 0.03$), *Arid2* (n = 3, $p = 0.001$) and *Kdm5c* (n = 3, $p = 0.0005$) knockout had significantly higher bioluminescence intensities. Double knockout of *Pik3r1+Pten* (n = 3) had significantly stronger luciferase activity compared to NTC (two-sided unpaired *t* test, $p < 0.0001$), but was not significantly different from knocking out *Pik3r1* or *Pten* alone (two-sided unpaired *t* test, N.S.). Double knockout of *Pik3r1+Stk11* (n = 2) had significantly stronger luciferase activity compared to NTC (two-sided unpaired *t* test, $p = 0.01$), but was not significantly different from knocking out *Pik3r1* or *Stk11* alone (two-sided unpaired *t* test, N.S.). In contrast, double knockout of *B2m+Kansl1* led to significantly higher luminescence intensities compared to NTC (two-sided unpaired *t* test, $p = 0.005$), *B2m* alone ($p = 0.001$) and *Kansl1* alone ($p = 0.02$). (D) Longitudinal IVIS live imaging of single or combinatorial AAV-CRISPR knockout of TSGs in driving liver tumorigenesis. The bioluminescence intensities of LSL-Cas9 mice injected with liver-specific AAVs containing either NTCs or sgRNAs targeting single gene or combinations of two genes. Left to right, *B2m + Kansl1*, *Pik3r1 + Pten*, *Pik3r1 + Stk11*, and *Arid2 + Kdm5c*.

Figure S11




fig. S11. Mutant clonality and clustering analysis. Gaussian kernel density estimate of variant frequencies within each mTSG liver sample. The number of peaks in the kernel density estimate is an approximation for the clonality of each sample. From this analysis, most (24/30) samples appeared to be composed of multiple clones, with six monoclonal samples.

Supplementary tables:

table S1. DNA sequences of sgRNA spacers in mTSG library.

table S2. Raw read counts of mTSG plasmid library.

table S3. Tumor volume data as measured by MRI.

table S4. Survival data for PBS-, vector-, or mTSG-treated animals.

table S5. Tumor area data as measured by tissue histology.

table S6. Sequence information and annotation for all MIPs used in the study.

table S7. Metadata for all of the 133 sequenced samples.

table S8. MIP capture sequencing coverage statistics across all predicted cutting sites of sgRNAs in AAV-mTSG library.

table S9. Raw indel variant calls of all samples with targeted capture sequencing before filtering.

table S10. sgRNA-level sum indel frequency table for all samples with targeted capture sequencing.

table S11. sgRNA-level binary MS calls in livers from mice treated with AAV-mTSG library.

table S12. Gene-level binary MG calls in livers from mice treated with AAV-mTSG library.

table S13. Co-occurrence analysis of MG pairs in livers from mice treated with AAV-mTSG library.

table S14. Correlation analysis of gene-level sum indel frequency in livers from mice treated with AAV-mTSG library.

table S15. Mutant frequencies for all unique variants present across all mTSG liver samples.

table S16. Spearman rank correlation matrix for five individual liver lobes within a single mouse.

table S17. Mutant frequencies for all unique variants present in five individual liver lobes from a single mouse.